- Home
- DGICA vs AUTL Comparison
DGICA vs AUTL Comparison
Compare DGICA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- AUTL
- Stock Information
- Founded
- DGICA 1986
- AUTL 2014
- Country
- DGICA United States
- AUTL United Kingdom
- Employees
- DGICA N/A
- AUTL N/A
- Industry
- DGICA Property-Casualty Insurers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGICA Finance
- AUTL Health Care
- Exchange
- DGICA Nasdaq
- AUTL Nasdaq
- Market Cap
- DGICA 683.3M
- AUTL 625.4M
- IPO Year
- DGICA N/A
- AUTL 2018
- Fundamental
- Price
- DGICA $17.59
- AUTL $1.75
- Analyst Decision
- DGICA Hold
- AUTL Strong Buy
- Analyst Count
- DGICA 1
- AUTL 5
- Target Price
- DGICA $18.00
- AUTL $9.12
- AVG Volume (30 Days)
- DGICA 163.2K
- AUTL 2.8M
- Earning Date
- DGICA 10-23-2025
- AUTL 08-12-2025
- Dividend Yield
- DGICA 4.17%
- AUTL N/A
- EPS Growth
- DGICA 965.80
- AUTL N/A
- EPS
- DGICA 2.34
- AUTL N/A
- Revenue
- DGICA $993,644,532.00
- AUTL $29,934,000.00
- Revenue This Year
- DGICA $2.26
- AUTL $472.28
- Revenue Next Year
- DGICA $2.96
- AUTL $114.92
- P/E Ratio
- DGICA $7.51
- AUTL N/A
- Revenue Growth
- DGICA 3.36
- AUTL 185.17
- 52 Week Low
- DGICA $14.06
- AUTL $1.11
- 52 Week High
- DGICA $21.12
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- DGICA 49.23
- AUTL 32.10
- Support Level
- DGICA $17.05
- AUTL $1.70
- Resistance Level
- DGICA $17.70
- AUTL $1.89
- Average True Range (ATR)
- DGICA 0.36
- AUTL 0.15
- MACD
- DGICA 0.11
- AUTL -0.06
- Stochastic Oscillator
- DGICA 84.68
- AUTL 11.49
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.